<DOC>
	<DOCNO>NCT01661387</DOCNO>
	<brief_summary>As post-approval requirement European Medicines Agency , European patient post authorization safety study observational study conduct monitor safety long-term treatment Plenadren glucocorticoid replacement therapy routine clinical practice patient chronic adrenal insufficiency ( primary secondary ) .</brief_summary>
	<brief_title>A European Post-Authorisation Observational Study ( Registry ) Patients With Chronic Adrenal Insufficiency ( AI )</brief_title>
	<detailed_description />
	<mesh_term>Adrenal Insufficiency</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Diagnosis chronic adrenal insufficiency Written inform consent/assent compliance applicable countryspecific local regulation Participation interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Adrenal insufficiency</keyword>
	<keyword>DuoCort</keyword>
	<keyword>Congenital adrenal hyperplasia ( CAH )</keyword>
	<keyword>Modified release</keyword>
	<keyword>Hydrocortisone</keyword>
</DOC>